The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D

Open source

DOI: 10.1002/alz.14342
Published: 2025 Jan
Container: Alzheimer's & dementia : the journal of the Alzheimer's Association
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/alz.14342,
  title = {The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.},
  author = {Aisen P and Bateman RJ and Crowther D and Cummings J and Dwyer J and Iwatsubo T and Kosco-Vilbois M and McDade E and Mohs R and Scheltens P and Sperling R and Selkoe D},
  year = {2025},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  doi = {10.1002/alz.14342},
  url = {https://doi.org/10.1002/alz.14342}
}

RIS

TY  - JOUR
TI  - The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.
AU  - Aisen P
AU  - Bateman RJ
AU  - Crowther D
AU  - Cummings J
AU  - Dwyer J
AU  - Iwatsubo T
AU  - Kosco-Vilbois M
AU  - McDade E
AU  - Mohs R
AU  - Scheltens P
AU  - Sperling R
AU  - Selkoe D
PY  - 2025
JO  - Alzheimer's & dementia : the journal of the Alzheimer's Association
DO  - 10.1002/alz.14342
UR  - https://doi.org/10.1002/alz.14342
ER  -

APA

P, A., RJ, B., D, C., J, C., J, D., T, I., M, K., E, M., R, M., P, S., R, S., & D, S. (2025). The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.14342

Source records

pubmed · retrieved 2026-09-26T20:43:50.453Z